CT colonography study demonstrates effectiveness of Medicsight CAD for colorectal cancer detection in symptomatic patients

London 09 March 2007Medicsight plc, a subsidiary company of MGT Capital Investments Inc., has announced the presentation of a study demonstrating the effectiveness of Medicsight ColonCAD for the detection of colorectal cancer in symptomatic patients. The study was presented on March 9, 2007 at the European Congress of Radiology (ECR) in Vienna, Austria by Professor Steve Halligan from University College Hospital, London.

Advertisement

Professor Halligan has been investigating the relatively unexplored area of CAD detection for colorectal cancers in symptomatic patients. In his ECR presentation, Professor Halligan provided the preliminary results from an ongoing study investigating the potential for CAD to detect colon cancers demonstrated on CT colonography. Many other studies have shown the value of ColonCAD, and this study supports the expansion of the clinical usage of ColonCAD, which has increasingly been advocated for the detection of adenomatous polyps in asymptomatic patients.

The study investigated 59 patients, each with proven cancers established by colonoscopy and histology. These patients were examined with Medicsight ColonCAD to analyse paired prone and supine datasets over a range of four user adjustable CAD filter settings. Across the range of settings, ColonCAD detected 47 to 54 of the 59 cancers. This means a sensitivity range of 88,7 percent - 91,5 percent.

Overall, the study showed Medicsight ColonCAD to be very effective in the detection of colon cancer on CT colonography. Both prone and supine datasets are required for optimal CAD results. David Sumner, chief executive officer of Medicsight plc, commented: "We are pleased with the findings of this study focusing on colorectal cancers in symptomatic patients. These exciting preliminary results validate and could further extend the potential use of the Medicsight Colon CAD in clinical practice."

MGT Capital Investments is an investment company with two direct subsidiaries that focus solely on the dynamic and consolidating health care IT sector. The first subsidiary, Medicsight plc, is a developer of computer-aided detection (CAD) and computer assisted reader (CAR) software solutions that are tested using one of the world's largest databases of verified CT scan data. Medicsight's CAD and CAR products help clinicians identify, measure, and analyse suspicious pathology, such as colorectal polyps and lung lesions.

MGT Capital Investments has invested in and controls a second subsidiary, Medicexchange plc, which operates Medicexchange.com, an on-line multi-vendor sales channel for diagnostic, treatment and surgery planning solutions for cardiac, thoracic, breast imaging, orthopaedic, and gastro-intestinal imaging. Medicexchange.com provides these solutions in a low-cost, on-demand and downloadable format, enhancing access to information and products for medical imaging professionals.

More news on Medicsight is available in the VMW January 2007 article Medicsight announces market release of ColonCAR software with significantly improved reader performance in published CT colonography study.


Leslie Versweyveld

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]